Advaxis Inc. (NASDAQ:ADXS)’s share price shot up 11.3% during mid-day trading on Monday . The stock traded as high as $16.05 and last traded at $15.87, with a volume of 2,160,888 shares changing hands. The stock had previously closed at $14.26.

Several research firms recently weighed in on ADXS. FBR & Co reissued an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a report on Tuesday, May 17th. HC Wainwright reissued a “buy” rating on shares of Advaxis in a report on Wednesday, June 29th. Jefferies Group reissued a “buy” rating on shares of Advaxis in a report on Thursday. Finally, Barclays PLC raised their price objective on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, August 3rd. Six research analysts have rated the stock with a buy rating, Advaxis presently has an average rating of “Buy” and a consensus price target of $25.80.

The company has a 50-day moving average of $8.71 and a 200 day moving average of $8.13. The company’s market cap is $522.27 million.

In related news, Director Thomas J. Mckearn sold 4,100 shares of the business’s stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total transaction of $30,545.00. Following the sale, the director now directly owns 82,120 shares in the company, valued at approximately $611,794. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.